Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study
{{output}}
Background: This double-blind, placebo-controlled, phase 2a clinical trial evaluated the efficacy and safety of JNJ-55308942 (zanvipixant), a selective, brain-penetrant P2X7 receptor antagonist, in bipolar depression. ... ...
